SAN DIEGO, Oct. 9 /PRNewswire/ -- Protein Polymer Technologies, Inc.
(OTC Bulletin Board: PPTI), today announced that J. Thomas Parmeter, President
and CEO, will present a Company update at the TechVest 3rd Annual Conference
on Tissue Repair, Replacement and Regeneration. The content of Mr. Parmeter's
remarks will focus on progress in the development and testing of PPTI's
injectable silk-elastin polymer formulations for the treatment of female
stress urinary incontinence, and for the treatment of dermal contour
deficiencies (facial lines, wrinkles, and scars). Both of these products are
in FDA-approved clinical trials. He will also comment on the development of
new applications for the Company's protein polymer technology.
The TechVest Conference, to be held October 23rd and 24th in New York
City, has become a premier event in the field of tissue repair and
regeneration, with presentations by more than 75 companies, as well as experts
from the medical and scientific community. Tied in with the conference will
be an "Emerging Healthcare Forum" and a scientific symposium sponsored jointly
with the New Jersey Center for Biomaterials on "Understanding Cells and
Materials for Tissue Engineering." PPTI has presented at the two previous
TechVest tissue engineering conferences.
"The combination of population demographics and increased demand for
improving one's appearance are rapidly expanding the markets for treatment of
incontinence and for dermal contour corrections," said J. Thomas Parmeter,
President and Chief Executive Officer of Protein Polymer Technologies, Inc.
"Physicians continue to seek safe, effective, and more durable treatments in
response to patient demand. These products are an ideal fit with our goal of
providing new classes of high performance biomaterials designed through
genetic and protein engineering to meet present and future needs in tissue
repair and regeneration."
Protein Polymer Technologies, Inc. (PPTI) is a San Diego-based company
focused on developing products to improve medical and surgical outcomes. From
its inception in 1988, PPTI has been a pioneer in protein polymer design and
synthesis, developing an extensive portfolio of proprietary biomaterials.
These genetically engineered biomaterials are high molecular weight proteins,
processed into products with physical and biological characteristics tailored
to specific clinical performance requirements. Targeted products in addition
to its dermal contouring product and urethral bulking agent for the treatment
of stress urinary incontinence, are tissue adhesive and sealant formulations
for the repair of spinal disks, scaffolds for wound healing and tissue
engineering, and depots for local drug delivery.
This press release contains forward-looking statements that are based on
management's views and expectations. Actual results could differ materially
from those expressed here; further, the Company is not obligated to comment
specifically on those differences. Risks associated with the Company's
activities include scientific and product development uncertainties,
competitive products and approaches, continuing collaborative partnership
interest and funding, regulatory testing and approvals, and manufacturing
scale-up. The reader is encouraged to refer to the Company's 2000 Annual
Report and 10-KSB, and recent filings with the Securities and Exchange
Commission, copies of which are available from the Company, to further
ascertain the risks associated with the above statements.
SOURCE Protein Polymer Technologies, Inc.
 back to top
Related links:
http://www.ppti.com
Company News On-Call:
http://www.prnewswire.com/comp/721876.html
CONTACT:
J. Thomas Parmeter, President, or John E.
Flowers, Vice President, Operations of Protein Polymer
Technologies, Inc., +1-858-558-6064, info@ppti.com
|
